Revumenib was developed and launched by which pharmaceutical company

Revumenib is an oral targeted drug developed and launched by Syndax Pharmaceuticals, an American biopharmaceutical company. It belongs to the category of menin inhibitors. This drug is mainly used to treat relapsed or refractory acute leukemia (including acute myeloid leukemia AML) with KMT2A translocation (KMT2A-r) or NPM1 mutation and acute lymphoblastic leukemia ALL), it is the world’s first menin target new drug approved for this type of leukemia, representing a new direction in epigenetic targeted therapy.

Syndax Pharmaceuticals was founded in 2005 and is headquartered in Massachusetts, USA. It is an innovative biopharmaceutical company focusing on the development of cancer epigenetic therapy and immunotherapy drugs. Revimeni is one of the company's most representative innovative products. In November of 202411, Revimenib received the USFDA approval It was quickly approved for marketing and was granted "breakthrough therapy", "orphan drug" and "priority review" status, which reflects its great clinical significance, especially in the treatment of KMT2A-r related leukemia that is ineffective with traditional therapies.

In a pivotal clinical trial (AUGMENT-101 study), revimenib demonstrated good response rates in a patient population who had failed multiple treatments. Data show that the drug can induce a complete response rate (CR/CRh) of more than 20% and a median response time of more than 6 months. In addition, it can take effect in a relatively short period of time (about 2 months), showing the potential for rapid control of acute leukemia. As its research expands in more mutated subtypes (such as NPM1mutatedAML), revimenib is gradually becoming an important treatment option for patients with relapsed and refractory leukemia.

Overall, the successful development and launch of Revemenib not only fills the gap in the treatment of KMT2A translocation-related leukemia, but also further consolidates Syndax Pharmaceuticals ’s innovative position in the field of targeted hematological tumor treatment. With the clinical advancement of more indications in the future, Revemenib is expected to provide a breakthrough new option for more patients with acute leukemia in the era of precision medicine.

Reference materials:https://www.drugs.com/